Abstract:Significant strides have been made in the development of cancer vaccines to combat malignant tumors. However, the natural immunosuppressive environment within tumors, known as the tumor microenvironment (TME), hampers the uptake and presentation of antigens by antigen-presenting cells (APCs) within the tumor itself. This limitation results in inadequate activation of immune responses against cancer. In contrast, immune cells in peritumoral tissue maintain their normal functions. In this context, we present an interesting approach to enhance cancer immunotherapy by utilizing engineered photosynthetic bacteria (PSB) and their outer membrane vesicles (OMVPSB) to capture and transport antigens to the outer regions of the tumor. We modified PSB with maleimide (PSB-MAL), which, when exposed to near-infrared (NIR) laser-mediated photothermal therapy (PTT), induced extensive cancer cell death and the release of tumor antigens. Subsequently, the NIR-phototactic PSB-MAL transported these tumor antigens to the peripheral regions of the tumor under NIR laser exposure. Even more intriguingly, PSB-MAL-derived OMVPSB-MAL effectively captured and delivered antigens to tumor-draining lymph nodes (TDLNs). This facilitated enhanced antigen presentation by mature and fully functional APCs in the TDLNs. This intricate communication network between PSB-MAL, the OMVPSB-MAL, and APCs promoted the efficient presentation of tumor antigens in the tumor periphery and TDLNs. Consequently, there was a notable increase in the infiltration of cytotoxic T lymphocytes (CTLs) into the tumor, triggering potent antitumor immune responses in both melanoma and breast cancer models. This cascade of events resulted in enhanced suppression of tumor metastasis and recurrence, underscoring the robust efficacy of our approach. Our interesting study, harnessing the potential of bacteria and OMVs to redirect tumor antigens for enhanced cancer immunotherapy, provides a promising path toward the development of personalized cancer vaccination strategies.

Engineered skin bacteria induce antitumor T cell responses against melanoma

Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity

In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity

Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses

Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy

Bacteria colonization in tumor microenvironment creates a favorable niche for immunogenic chemotherapy

Microbiota-induced plastic T cells enhance immune control of antigen-sharing tumors

Programmable Bacteria with Dynamic Virulence Modulation System for Precision Antitumor Immunity

Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity

Engineered Bacteria Enhance Immunotherapy and Targeted Therapy through Stromal Remodeling of Tumors

Genetically Designed Living Bacteria with Melanogenesis for Tumor‐Specific Pigmentation and Therapeutic Intervention

Engineering bacteria for cancer immunotherapy

In Situ Synthesis of an Immune-Checkpoint Blocker from Engineered Bacteria Elicits a Potent Antitumor Response

Engineering Bacteria and Their Derivatives for Cancer Immunotherapy

Programmed Nanocloak of Commensal Bacteria-Derived Nanovesicles Amplify Strong Immunoreactivity against Tumor Growth and Metastatic Progression

Self-adjusting Engineered Probiotic for Targeted Tumor Colonization and Local Therapeutics Delivery

Redirecting Antigens by Engineered Photosynthetic Bacteria and Derived Outer Membrane Vesicles for Enhanced Cancer Immunotherapy

Tumor-targeting bacteria as immune stimulants – the future of cancer immunotherapy?

Nanobody‐Engineered Biohybrid Bacteria Targeting Gastrointestinal Cancers Induce Robust STING‐Mediated Anti‐Tumor Immunity

Tweak to Treat: Reprograming Bacteria for Cancer Treatment